Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | DDOST | P39656 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25728331 | 1.00 | DPP7 (0.47) | DPP7PRCPNOS2NOS3NOS1 | |
| SCHEMBL30866235 | 1.00 | DPP7 (0.47) | DPP7PRCPNOS2NOS3NOS1 | |
| SCHEMBL19258205 | 0.89 | DPP7 (0.46) | DPP7PRCPNOS2NOS3NOS1 | |
| SCHEMBL19138319 | 0.89 | DPP7 (0.46) | DPP7PRCPNOS2NOS3NOS1 | |
| SCHEMBL17469367 | 0.89 | DPP7 (0.46) | DPP7PRCPNOS2NOS3NOS1 | |
| SCHEMBL17469380 | 0.89 | DPP7 (0.46) | DPP7PRCPNOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL28600561 | 0.88 | DPP7 (0.45) | DPP7PRCPNOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL28600562 | 0.88 | DPP7 (0.45) | DPP7PRCPNOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL28600564 | 0.88 | DPP7 (0.45) | DPP7PRCPNOS2NOS3NOS1 | |
| SCHEMBL16853543 | 0.87 | DPP7 (0.49) | DPP7PRCPCTSCCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622994-B2 | Therapy for vitiligo | CLINUVEL PHARMACEUTICALS LIMITED (AU) | 2023-04-11 | — | — | US | claimed |
| CN-114292312-A | Method for synthesizing 9 peptide-1 in full liquid phase | 湖南微肽生物医药有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025123055-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11622994-B2 | Therapy for vitiligo | CLINUVEL PHARMACEUTICALS LIMITED (AU) | 2023-04-11 | — | — | US | disclosed |
| US-11332499-B2 | Cyclic peptides and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114292312-A | Method for synthesizing 9 peptide-1 in full liquid phase | 湖南微肽生物医药有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332499-B2 | Cyclic peptides and methods of use thereof | ANPEP, NPR3, XPNPEP1 | DPP7 316/4885PRCP 176/4885NOS2 1582/4885 |
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | DPP7 155/4885PRCP 706/4885NOS2 956/4885 |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | DPP7 109/4885PRCP 191/4885NOS2 3907/4885 |
| US-11622994-B2 | Therapy for vitiligo | MC1R, MC3R, MC5R | DPP7 2268/4885PRCP 704/4885NOS2 3285/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | DPP7 109/4885PRCP 191/4885NOS2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.